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Receptors  for C3b  and  C4b  (CR1) 1 are  found  on  the  membrane  of phagocytes 
where  they  promote  the  binding  of C3b-  or  C4b-bearing  particles  and  immune 
complexes (IC) (reviewed in  1). The majority of CR1 in the vascular system, however, 
is  present  on  erythrocytes in  primates  and  platelets  in  other  species.  Furthermore, 
CR1 is found on B lymphocytes (2, 3)  and on the epithelial cells of kidney glomeruli 
(4). The function of CR1 in these locations is unknown. 
In the present paper, we describe a new activity of CRa; that is, its participation in 
the  breakdown  of C3b  associated  with  IC.  This  investigation  was  prompted  by 
previous  observations  that,  when  soluble  IC  were  added  to  a  mixture  of normal 
human  serum  and  autologous unseparated  blood cells,  they fixed complement  and 
bound predominantly to the erythrocytes. The binding was mediated principally via 
C3 incorporated into the IC (5, 6). After complement fixation, the binding could not 
be prevented by preincubation of the IC with the serum enzyme C3b/C4b inactivator 
(I) and cofactor fllH  (H), but after binding, the IC could be released by treating the 
erythrocytes with I alone  (7, 8).  During this treatment,  C3b in the IC was degraded 
beyond the iC3b stage, a  fragment  the size of C3c was released,  and the IC became 
more  reactive  with  cells  bearing  C3d  receptors  (CR2).  This  was  unexpected,  as 
previous  reports  indicated  that  the  interaction  of fluid  phase  C3b  with  I  in  the 
presence of H  (9,  10) or of purified CR1  (11)  generated only the iC3b intermediate. 
Here,  we  study  the  nature  of  the  human  erythrocyte  factor  involved  in  the 
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1  Abbreviations used in this paper:  A, antibody to sheep erythrocytes; Ag:Ab, antigen:antibody complexes 
prepared with a soluble antigen; BSA, bovine serum albumin; C, complement; C3b, major fragment of 
C3; iC3b, cleavage product of C3b; C3c and C3d, not well defined cleavage products of iC3b by plasmin, 
trypsin or elastase; C3b*, iC3b*, C3d*, cell-bound or immune-complex-bound forms of the corresponding 
C3  fragments; CRa, membrane  receptor for C3b  and  C4b;  CR2, membrane  receptor  for C3d;  CR3, 
membrane receptor for iC3b; DVB, isotonic veronal buffered saline containing 2.5% dextrose, 0.15 mM 
CaCI2, and 1 mM MgC12; DOVB, DVB supplemented with 0.1% ovalbumin; DGVB, DVB supplemented 
with  0.1% gelatin; E,  sheep erythrocytes;  H,  fllH;  I,  C3b,C4b-inaetivator;  IC,  immune  complexes; 
K76COOH, K76 rnonocarboxylie  acid; PMSF, phenylmethylsulfonyl fluoride; SDS-PAGE, sodium dodecyl 
sulfate-polyacrylamide gel electrophoresis. 
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sequential breakdown of C3b bound to IC in the presence of I and further characterize 
the  C3-derived products of this  process.  We show  that  this  factor  is  CR1  itself.  In 
addition, we present suggestive evidence that  iC3b bound to IC is also a  ligand for 
CRa. To facilitate exposition, C3 fragments bound to IC after fixation of C3b, initial 
cleavage ofa' chain, and release of C3c will be designated with asterisks: C3b*, iC3b*, 
and C3d*, respectively. 
Materials and Methods 
Buffers.  Isotonic veronal-buffered saline containing 2.5% dextrose,  0.15 mM CaCI2, and 1 
mM MgCl2  (DVB)  was  used for all studies. DVB was supplemented with 0.1% ovalbumin 
(DOVB)  for studies with soluble IC, and with 0.1% gelatin (DGVB)  for studies with cellular 
intermediates. 
Proteins and Antibodies.  Four monoclonal antibodies to CR1 (57H, 44D, 57F, and 31D) were 
obtained as described elsewhere  (12). Polyclonal antibodies to C3c and C3d were  a gift  from 
Dr. Brian Tack (Scripps  Clinic and Research Foundation, La Jolla, CA). These antisera were 
raised in rabbits by injecting them with C3c and C3d purified from elastase digests of C3 (13), 
CRa was purified from human erythrocytes as described in ref.  11, except that the last two 
steps,  that  is,  affinity chromatography  on  Sepharose-lentil lectin  and  Sepharose-C3,  were 
substituted by  affinity chromatography on  Sepharose-anti-CR1 prepared  with  monoclonal 
antibodies (14). 
H  (15), I (16), C4-bp (17), and C4 and C3 (13) were purified from human serum or plasma 
as described. C3 provided by Dr. John Atkinson (Washington University School of Medicine, 
St.  Louis,  MO)  was  used  in some studies. C2  was  purified as  described  (13),  followed by 
chromatography on CM-Sephadex C-50 and DE-52, and was used in an oxidized form (°xYC2) 
(18). C5 was purchased from Cordis Laboratories, Miami, FL. C3b was prepared by incubating 
C3 with factors  B (19) and D  (20) and isolated as described (16). Plasminogen was  purified 
from human serum (13) and activated by urokinase (Sigma Chemical Co., St. Louis, MO) (21). 
C1  (22) and C6-9 (23) were prepared from guinea pig serum. 
Cellular Intermediates and Hemolytic Assay.  Sheep erythrocytes (E) were sensitized with rabbit 
hemolysin (A),  (Gibco Laboratories, Grand Island Biological  Co.,  Grand Island, NY),  and 
complement components C1,  C4,  and °xyc2 were  added sequentially to yield 300 hemolytic 
sites per cell. Then radiolabeled C3 was  added in an appropriate dilution to yield between 
three and five hemolytic sites per cell. After incubation, the EAC1423b cells were washed and 
resuspended in DGVB. To prepare EAC1423bi, the EAC1423b cells (10S/ml)  were incubated 
at 30°C for 60 min with I (2/~g/ml) and H  (5 ~g/ml). The remaining C3 hemolytic activity on 
these cells was measured by incubating  cells with excess C5 at 30°C for 5 min and an additional 
60 min at 37°C with C6-9. In some experiments, EAC14 cells were prepared with radiolabeled 
C4. 
Radiolabeling.  C3,  C3b,  and  C4  were  labeled  with  125I using  Enzymobeads,  (Bio-Rad 
Laboratories, Rockville Center, NY) or lactoperoxidase beads (Worthington Biochemical Corp., 
Freehold, N  J) according to the instructions of the manufacturer. 
Analysis  of Membrane-bound C3 Fragments.  C3  peptides  from  erythrocyte membranes were 
prepared as described by Law et al.  (24). Briefly,  6 X  10  7 of EAC1423b or EAC1423bi were 
lysed with distilled water containing 1 mM phenylmethylsulfonyl  fluoride (PMSF), and ghosts 
were collected  by centrifugation. The pellets were solubilized with 25/tl of 0.1% Triton-X in 15 
mM  Tris  buffer  (pH  7.8) containing  1  mM  PMSF  and  incubated  with  25  /.tl of  1  M 
hydroxylamine in 2 M  sodium carbonate buffer (pH 9.5) for 30 min at 37°C. After dialysis 
against phosphate-buffered saline  (pH  7.4) the  samples were  analyzed by sodium dodecyl 
sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) followed by radioautography. 
Isolation of Human Erythrocytes.  Human erythrocytes were isolated by incubation of heparin- 
ized  blood with dextran (25), followed  by centrifugation of sedimented cells through Ficoll- 
Hypaque (d =  1.094) and washing and resuspension of the pellet. Separated cells contained M.  E.  MEDOF,  K.  IIDA, C.  MOLD,  AND V.  NUSSENZWEIG  1741 
<4  X  104 white blood cells per 5 X  109 erythrocytes. 
Preparation and  Isolation of  Soluble Antigen  (Ag)-Antibody  (Ab)-Complement (C)  Complexes 
(Ag:Ab:C).  Ag:Ab complexes were prepared  from  bovine serum  albumin  (BSA)  and  heat- 
inactivated guinea pig antiserum to BSA. Antibody was raised and the antigen/antibody ratio 
at equivalence was determined as previously described  (5).  Anti-BSA was diluted sufficiently 
that  when  mixed with  BSA at  equivalence, no precipitate  formed.  Ag:Ab were prepared  in 
fourfold antibody excess, so that, after reaction of Ag:Ab with serum, Ag:Ab:(] gave maximum 
percentage binding (~75%)  to human erythrocytes (5, 6). 
125I-C3-1abeled  Ag:Ab:C were prepared  by mixing one vol of Ag:Ab with an equal volume 
of 1:16 diluted normal human serum supplemented with x25I-C3 (10 ng/#l of 1:16 serum)  and 
with the I-inhibitor K76 monocarboxylic acid (K76COOH)  (26), a  gift from Dr. Kozo Inoue, 
Osaka University, Japan,  at  a  final concentration of 4  mM. After incubation  at  37°(]  for 30 
min, the reaction mixture was diluted twofold with ice-cold DOVB. 
Ag:Ab:C bearing  125I-(]3 were separated  from free 125I-C3 or (]3b  and  K76COOH  by gel 
filtration  through  Biogel A1.5m  (Bio-Rad  Laboratories)  equilibrated  with  DVB  at  4°C.  A 
typical elution profile is shown  in Fig.  1, together with an elution profile of z25I-BSA-labeled 
Ag:Ab:(] for comparison.  Ag:Ab:C eluted  as  a  single symmetrical  peak  at  the void volume. 
80% of added label was recovered in this peak in the case of the I25I-BSA-labeled preparation. 
50 #1 of individual column fractions was added to suspensions of human or sheep erythrocytes 
(2 ×  l0  s cells in DOVB), the mixtures were incubated at 37°(] for 15 min, and the cells were 
washed.  Fractions  containing  Ag:Ab:C, giving high  binding  to  human  and  low binding  to 
sheep erythrocytes, were pooled and used immediately. 
SDS-PAGE.  SDS-PAGE was performed as described by Laemmli (27).  3.75% stacking and 
5-15% gradient running gels were used in most cases. A pool of proteins from a commercial kit 
(Bethesda  Research  Laboratories,  Inc.,  Rockville, MD)  was  used  to  estimate  the  molecular 
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FIG.  I.  Purification of Ag:Ab:C by gel  filtration and  analysis  of their binding properties.  The 
reaction mixture obtained after incubation of unlabeled Ag:Ab with  1:16 diluted serum supple- 
mented with 1251-C3 and K76COOH, as described  in Materials and Methods, was applied to a  2 
×  100-cm column containing Biogel  A1.5m  equilibrated  with  DVB,  and  500-~1 fractions  were 
collected.  The elution pattern (O) is shown along with the elution pattern  (0) of a control reaction 
mixture obtained after identical incubation of ]25I-BSA-labeled Ag:Ab with untreated  1:16 diluted 
serum.  In the latter case, >80% of the BSA label was recovered in the void volume. 50 btl aliquots 
of individual column fractions  of ]~sI-C3-1abeled Ag:Ab:C were incubated at 37°C for 10 min with 
human or sheep erythrocytes (HUE, ShE) and, after washing,  percentage binding was determined. 1742  UNIQUE  ROLE  OF CRI  IN C3b  DEGRADATION 
weights  of samples  run  under  reducing  conditions.  Rabbit  IgG,  F(ab')2,  Fab,  and  bovine 
albumin were used as molecular weight markers when samples were analyzed under nonreduc- 
ing conditions. After electrophoresis, gels were stained with Coomassie blue or with the silver 
staining kit (Upjohn Diagnostics, Kalamazoo, MI). Radioautography was carried out at -70°C 
using X-Omat R  film (XR-5, Eastman Kodak Co., Rochester, NY). In some instances, proteins 
were eluted from bands excised from the acrylamide gels, using the technique described in ref. 
28. 
Two-Dimensional Electrophoresis.  A modified O'Farrell technique (29) was used as described 
(30). Electrofocussing was performed in the first dimension. A mixture ofAmpholines, pH 3-10, 
5  8, and 9  11  (LKB Instruments, Inc., Rockville, MD), was used to obtain a pH range of from 
5.1  to 9.1 The second dimension (SDS-PAGE) was carried out in a  5  15% gradient gel. The 
slab gels were then subjected to radioautography. 
Results 
Ability of Purified CR1  +  I to Release C3 Fragments  from EAC1423b.  Because previous 
studies  had  shown  that  C3  fragments  produced  during  release  of Ag:Ab:C  from 
human  erythrocytes by I  differed from  those obtained after exposure of fluid phase 
C3b  to  !  +  H  or  to  I  +  CR1,  the  effects  of each  of these  factors  on  C3b*  were 
compared using the cell intermediate EAC1423b  prepared with  125I-C3  and bearing 
five hemolytic sites per cell. Cells (10S/ml in DGVB,  containing ~0.13 ~g of C3b*/ 
ml) were mixed at 30°C with I  (2/~g/ml), CR1  (100 ng/ml), or H  (5/~g/ml), or with 
mixtures  of I  +  H  or  I  +  CR1  at  the  same  final  concentrations.  At  various  time 
intervals (from 5 to 50 min)  duplicate 100-~1  samples of each mixture were removed, 
mixed with 2 ml of ice-cold DGVB, and centrifuged at 600g for 10 min. In one set of 
samples, the radioactivity in the pellets and  supernatants  was counted  in a  gamma 
counter. In the other set, the residual hemolytic activity of EAC 1423b was measured. 
The  results  (Fig.  2 a)  show  that  within  a  few  minutes  of incubation  of EAC1423b 
with I  +  H  or with I  +  CRx or CR1 alone, C3 hemolytic activity was abolished. The 
results  agree  with  previous  findings  that  I  +  H  can  transform  EAC1423b  into 
hemolytically inactive EAC1423bi  (9,  15)  and that CR~ alone can inhibit EAC1423b 
hemolytic sites (31). 
In  contrast,  as  shown  in  Fig.  2 b,  only  !  +  CR1  released  large  amounts  of C3 
fragments  from  the  cells.  At  30  min  of incubation  with  I  +  CR1  ~70%  of the  C3 
radioactivity was  found  in the supernatant,  whereas <10%  was  specifically released 
by I or by I  +  H. Under the same conditions, we incubated EAC14 cells bearing five 
hemolytic sites per cell and prepared with radiolabeled C4, with  I  (2 ~g/ml)  +  CR1 
(100 ng/ml), or with I +  C4bp (1 ~g/ml). The amount of radioactivity released in the 
supernatant  during  1 h  of incubation  at  30°C  was  negligible and  not  significantly 
different from that released from cells incubated with buffer alone. 
In a separate experiment (not shown), we studied the effects of the concentration of 
I  and  CR1  on  the  release of C3  fragments  from  the EAC1423b  cells. The  extent  of 
release was  higher  as the  concentration  of either  reagent  was  increased.  Moreover, 
when the dose of CR1  was diminished, the release could be enhanced by an increase 
in the dose of I and vice versa.  12% of the C3b* counts were released specifically from 
cells incubated for 30 min at 30°C with  12.5  ng/ml of CR1  and 4/~g/ml of I. About 
9%  release was  observed  in  the  presence  of  125  ~g/ml  of H  and  12.5  /~g/ml  of I. 
Considering that the molecular weights of the subunits of CR1  and  H  are ~200,000 M.  E.  MEDOF,  K.  IIDA, C.  MOLD,  AND V.  NUSSENZWEIG  1743 
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Fio. 2.  Interaction of CRI, I, and H with EAC1423b. Time-course of inactivation of hemolytic 
activity (A) and of release of C3 fragments (B). EAC 1423b (10  s cells/m  l), prepared with radiolabeled 
C3 and bearing five hemolytic sites per cell, were mixed with I (2 #g/ml), CRa (I00 ng/ml), H (5 
#g/ml), or mixtures of I +  CR] or I +  H at  the same final concentrations. At timed intervals, 
duplicate samples of 100 #1 were withdrawn from each tube and mixed with 2 ml of ice-cold DGVB. 
One set of samples was used to test the hemolytic activity remaining on EAC 1423b. The other tubes 
were centrifuged, and the radioactivity in the supernatants and pellets was counted in a gamma 
counter. The results indicate that  while CR1 +  I, H +  I, or CR] alone inhibited the hemolytic 
activity oferythrocyte intermediates, only CR] + I released large amounts of C3 fragments from the 
cells. 
and  150,000, respectively, on a  molar basis, the CR1  activity is at  least  104 greater 
than that of H. 
Effect of Membrane-associated CR1 on C3b*  in the Presence of I.  The effects of isolated 
CR1 and membrane-associated CR1 on EAC 1423b are compared in Fig. 3. EAC 1423b 
(10S/ml) and I (2/xg/ml) were incubated at 30°C for 30 min with increasing numbers 
of washed human erythrocytes or with the equivalent amounts of purified CR1  (400 
ng/109 human erythrocytes) (12), and the reaction was terminated as described above. 
As shown, C3 fragments were released from EAC1423b by both human erythrocytes 
and purified CR1 in a  dose-dependent fashion. Moreover, the specific activities of the 
intact erythrocytes and purified CR1 were almost identical. That the human eryth- 
rocyte activity was mediated exclusively by CRa was shown by its complete inhibition 
in the presence of 2 #g/ml of pooled purified monoclonal antibodies to CRa. 
Evidence  That  iC3b*  Is a  Ligand for CRI.  Previous observations have  shown that 
CR1  +  I  or H  +  I  cleave the a' chain of fluid-phase C3b and generate iC3b. One 
trivial explanation for the finding that CR~ +  I  but not H  +  I  can fragment C3b* 
beyond  the  iC3b*  stage  is  that  CRI  is  contaminated  by  a  proteolytic  enzyme. 
Alternatively, the  reaction between C3b*, CR],  and I  could  proceed  in two  steps, 1744  UNIQUE  ROLE  OF CR~  IN  C3b  DEGRADATION 
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Fro.  3.  Inhibitory effect of anti-CR1 on the release of C3 fragments from EAC1423b by human 
erythrocytes and I. EAC 1423b prepared with radiolabeled C3 and bearing three hemolytic sites per 
cell (108 cells/ml) were incubated with I (2/~g/ml) and human erythrocytes (0) or purified CRa 
(~), in the presence (O) or absence of monoclonal anti-CR1 (2.5 #g/ml) for 30 rain at 30°C. The 
final concentrations of CRI or human erythrocytes in the reaction mixtures are indicated on the 
abscissa. The input of C3 counts per tube was 4.4 ×  104. The results show that  the erythrocyte 
activity was inhibited by the monoclonal antibodies. 
both requiring CR1. 
To distinguish between these possibilities, we studied the activity of CR1 +  I on the 
intermediate EAC 1423bi prepared with radiolabeled C3. To prepare EAC 1423bi, we 
incubated EAC 1423b with I +  H, as described in Materials and Methods, and washed 
the cells by centrifugation. Hemolytic assays showed no residual C3b* sites, and direct 
analysis  by  SDS-PAGE  of  the  hydroxylamine-treated  membranes  of  these  cells 
demonstrated that the a' chain of C3b* had been cleaved (inset of Fig. 4). 
The EAC1423bi were then incubated at 37°C in the presence of buffer, I, CR1, or 
CR1  +  I.  In the presence of CR1  +  I  (but not CR1  or I  alone) C3  fragments were 
released in the supernatant (Fig. 4).  Moreover, release also occurred when the cells 
were first exposed to CR1 alone, washed thoroughly, and then incubated with I. That 
the release was CR1 mediated was shown by its complete inhibition when monoclonal 
antibodies to CR1 (5/~g/ml) were added to the incubation medium. As an additional 
control,  other  tubes  containing EAC1423bi  were  incubated with  plasmin.  In  this 
instance,  the  release  of C3  fragments  could  not  be  inhibited by  the  monoclonal 
antibodies. These results demonstrate that  EAC 1423bi has binding affinity for CR1 
and that the further degradation of iC3b* in the presence of I is CR1 dependent. 
Structure of the Fragments Released by  CR1  +  I from  EAC1423b.  The C3  fragments 
released in the supernatant of the reaction between EAC 1423b with CR1 +  I or with 
human erythrocytes +  I were analyzed by SDS-PAGE. No significant variation was 
observed in their structure when the time of incubation at 30°C varied from 5 to 75 
min.  As  shown  in  Fig.  5,  their  apparent  molecular  weight  was  ~135  K  under 
nonreducing conditions. After  reduction, two  main  labeled polypeptides were  de- 
tected: JR chain and a  fragment with an apparent molecular weight of 31,000, most 
likely derived from the a' chain (Fig. 6). When gels were overexposed, weak 70-K and 
40-K bands were observed. The structure of the fragments released in small amounts 
by H  +  I was identical (data not shown). 
The  135-K fragment was further identified as C3c because it could be specifically 
immunoprecipitated with an antiserum to C3c but not to C3d.  Moreover, the 31-K 
polypeptide isolated from bands excised from the slab gels also reacted with anti-C3c. M.  E.  MEDOF, K.  IIDA, C.  MOLD,  AND V.  NUSSENZWEIG  1745 
FIc. 4.  Release  of C3 fragments from EAC1423bi by CR1 + I or plasmin. EAC1423bi (10  s cells/ 
ml) were incubated with plasmin (10 #g/ml),  or CR1 (400 ng/ml)  or CR1 +  I (4/.tg/ml) in the 
presence or absence of anti-CR1 (5 #g/ml) at 30°C. Alternatively, EACI423bi were first incubated 
with CR1 for 30 min at 30°C, washed thoroughly, and used for the kinetic studies of C3 release by 
I alone. At timed intervals, 100 ~1 of reaction mixtures were withdrawn into tubes with 2 ml ice-cold 
DGVB, centrifuged, and the radioactivity in pellets and supernatants counted. In the figure, the 
symbol / represents a washing step before the addition of reagent  (s) to the erythrocyte intermediate. 
The results demonstrate that CRa interacts with EAC 1423bi and that C3bi* can be further cleaved 
in the presence of I. That the activity is mediated by CR1 itself and not a contaminant enzyme is 
shown by the inhibition of the reaction with monoclonal  antibodies to the receptor. As expected, the 
monoclonals  did not interfere with the activity of plasmin. The inset of this figure contains the SDS- 
PAGE analysis of the membranes of the EAC 1423b and EAC 1423bi cells, prepared as described in 
Materials and Methods. After treatment with H + I, the a' chain of C3b was cleaved. 
(These antisera were directed against fragments purified from elastase-digests of C3.) 
Possible explanations for  the  discrepancy between  the  molecular weight  of C3c 
under  nonreducing conditions  (135,000)  and  the  molecular weights  of  the  major 
observed bands (75 K  and 31  K)  under reducing conditions are that the 3 I-K band 
represents two polypeptide chains or that C3c contains a weakly labeled peptide. The 
31-K peptide could not be resolved by two-dimensional electrophoretic analysis, and 
its pI was found to be 8.6. In other experiments, we analyzed supernatants originating 
from  EAC1423b  cells  prepared  with  100  times  more  C3.  Silver stain  of  the  gels 
revealed two C3-derived bands at 39 K  and 42 K  (not shown). 
The  breakdown  products  released  by  plasmin are  also  shown  in  Figs.  5  and  6 
because this enzyme has  been used  frequently by others  to  generate C3c  and C3d 
fragments. Clearly, the C3c fragments obtained with plasmin and with CR1 +  I differ 
greatly in structure. Uner nonreducing conditions, some free fl chain was detected in 
the  plasmin C3c,  but  the  main fragment had  an  ~66-K tool  wt.  Under reducing 
conditions, three peptides were detected of 75  K  (,8 chain), 60 K, and 27 K  tool wt. 
It should be pointed out  that plasmin cleaves the fl chain of fluid-phase iC3b  (32). 
That plasmin probably also cleaves the fl chain of fluid-phase iC3b* is shown in Fig. 
6: the intensity of the fl chain band in track CR1 +  I is stronger than that of plasmin 
+H+I. 
In addition, Fig. 6 shows the products obtained by incubation of radiolabeled fluid- 
phase C3b with I +  CR1 or I +  H. As expected (10, 11), the 70-K and 40-K fragments 1746  UNIQUE  ROLE  OF CR,  IN C3b  DEGRADATION 
Fro.  5.  SDS-PAGE  analysis under nonreducing conditions of the cleavage products released from 
cell-bound C3b*. EAC1423b (108 cells/ml), prepared with  radiolabeled C3  and bearing three 
hemolytic sites per cell, were incubated with I (2/.tg/ml) + H (5/lg/ml) for 60 min at 30°C, washed, 
and further incubated with plasmin (10 ~g/ml) for 60 rain. The EACI423b cells  were also incubated 
with I (2 lag/ml) + CR, (100 ng/ml) or with I + human erythrocytes (2.5 × 108 cells/ml) for 60 min 
at  30°C. The cells were centrifuged and the supernatants were analyzed by SDS-PAGE under 
nonreducing conditions and radioautography. The positions  of rabbit IgG and its fragments and of 
BSA in the stained gel are indicated. It is apparent that the main fragment released by CRI + I or 
human erythrocytes + I, has a molecular weight of- 135,000. Moreover, its structure differs from 
that of the fragment resulting from the activity of plasmin on EAC1423bi. 
of the a' chain were  generated. When the  radioautographs were overexposed,  faint 
39-K  and  31-K bands were  observed  in  the  tracks  containing the  product  of the 
reaction between CR1  +  I  and C3b.  The  39-K radiolabeled peptide and the  39-K 
silver stained band found upon SDS-PAGE of C3c  may be identical. This peptide 
may be poorly labeled when C3 rather than C3b is radioiodinated (33). 
Ability of CR1  +  I  to Cleave C3 Bound to Soluble Ag:Ab:C.  Soluble BSA-anti-BSA-C 
complexes bearing radiolabeled C3 fragments were purified as described in Materials 
and Methods.  About 80%  of the C3  associated with these complexes bound to  the 
surface membrane of human erythrocytes but not to sheep erythrocytes. The binding 
was CR1  mediated because treatment of the human erythrocytes with 50 ng/ml of 
pooled monoclonal anti-CRj antibody before addition of Ag:Ab:C completely abol- 
ished binding, and treatment with 4 btg/m[ anti-CR1 after binding released >50% of 
Ag:Ab:C. 
The following experiment was performed to determine whether isolated CR1 could 
serve  the  function of intact erythrocytes  (7)  in the  I-associated cleavage of the  C3 
bound to the  Ag:Ab:C and to compare its effect  to  that  of H.  Aliquots of 125I-C3- 
labeled Ag:Ab:C were incubated at 37°C for 30 min with DOVB, I, H, CR1, H  +  I, 
CRa  +  I, or human erythrocytes  +  I.  Samples of each  reaction mixture were  then 
subjected to SDS-PAGE under reducing conditions, and the radioautograph patterns 
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Fie.  6.  SDS-PAGE analysis under reducing conditions of cleavage products released from cell- 
bound C3b*.  The supernatants, obtained as described in the legend of Fig. 4, are analyzed here 
under reducing conditions. In addition, for comparison, we analyzed the cleavage products of fluid 
phase C3b by I +  H  and I +  CR1. For this purpose, radiolabeled C3b (0.25 #g/ml) was incubated 
for 3 h  at 37°C with I  (2/.tg/ml) +  CR~ (200 ng/ml) or with I  +  H  (20/.tg/ml). The results show 
that the fragment released frona EAC 1423b by CR] 4- I contains mainly radiolabeled fl chain and 
a  31-K peptide. The structure of the fragment released by plasmin is quite different, and contains 
some fl chain, a 60-K, and a  27-K peptide. The intensity of the fl chain band is reduced, suggesting 
that it was broken down by the activity of plasmin. The treatment of fluid-phase C3b resulted in 
the cleavage of the a' chain into 70-K and 40-K polypeptides. 39-K and 31-K polypeptides could 
be seen in the radioautographs of the tracks containing the reaction products of CR1 4- I with fluid- 
phase C3b when the radioautograph was overexposed (data not shown). 
Fxo.  7.  SDS-PAGE  analysis  of cleavage  products  of C3  after  treatment  of soluble  immune 
complexes with  H,  I, CR1, and  human erythrocytes,  a2sI-C3-1abeled  Ag:Ab:C were  incubated  at 
37°C for 30 rain with DOVB, I alone (1.6 pg), H  alone (32 pg), or CR] alone (0.16 pg) or I (1.6/Lg) 
+  H  (32/~g) or CR~  0.0025 pg or 0.04 #g) +  I  (0.1  /.tg or  1.6 #g) or HuE (6 X  106 or  l0  s  )  +  I  (0.1 
pg or  1.6 pg) in a  total volume of 150 pl. Samples of each reaction mixture were assessed by SDS- 
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FIG. 8.  Time-course of cleavage by CR1  +  I of C3 associated with soluble immune  complexes. 
Aliquots of 125I-C3-1abeled  Ag:Ab:C were added to equal  volumes of a solution of I  (2 btg/ml) + 
CR1 (50 ng/ml) and incubated at 37°C. Reactions were stopped after various times by addition of 
K76COOH  (4 mM) and transfer to ice. Samples were subjected to SDS-PAGE 5-15% gradient gels 
under reducing conditions, followed by radioautography. 
The  major radioactive C3  fragments  associated with  the  starting Ag:Ab:C  (first 
track on  left)  presumably  represent  intact fi chains, and,  in  addition, on  top of the 
gel,  a'  chain-derived  peptides  bound  tightly  (covalently  or  through  hydrophobic 
bonds) to components of the Ag:Ab:C (24, 34-36). In addition, C3 framents of 105-K 
(a'),  70-K,  and  40-K  tool wt  and  small  amounts  of material of lower tool  wt  were 
detected.  2 After incubation with H  or CR1, little change was detected in the structure 
of C3 associated with IC, except that  small amounts  of 36-K peptides were  formed. 
Incubation with I  or H  +  I  led to the appearance of a  light 31-K band and a  change 
in the pattern of the high tool wt bands. 
More conspicuous  modifications occurred when  the  complexes were  treated  with 
CR1  +  I: the intensity of the high tool wt C3 bands diminished, and simultaneously 
a  31-K band appeared. The intensity of the 31-K band was dependent on the dose of 
CRx and I. When the concentration of I was decreased, a  36-K band was also observed 
in  the  radioautographs,  suggesting  that  it  may  be  an  intermediate  product.  The 
degradation of C3 was even more pronounced after incubation with human erythro- 
cytes  +  I.  At  the  highest  concentration  of  erythrocytes  +  I,  little  radioactivity 
remained at  the top of the gel, and the band at  31-K was most  prominent  (track on 
the right side of Fig. 7). The radioactivity remaining on top of the gel could represent 
C3d* fragments of the a' chain covalently associated with constituents of the Ag:Ab:C. 
Next,  we  studied  the  time-course  of appearance  of the  31-K  peptide.  Separate 
aliquots of 125I-C3-1abeled Ag:Ab:C were added to equal  volumes of a  solution of I 
(2/tg/ml)  +  CR1  (200  ng/ml),  the  mixtures  placed at  37°C,  and  reactions stopped 
after various times (from 0.5 to 30 rain)  by addition of K76COOH  (final concentra- 
tion, 4  raM)  and transfer to ice. Samples of each reaction mixture were subjected to 
SDS-PAGE, and radioautograph patterns were analyzed. 
As seen in Fig, 8, within 0.5 rain of incubation, some 31-K peptide was generated. 
Its  intensity  as  well  as  that  of  other  peptides  (70-K,  40-K,  and  36-K)  increased 
progressively  during  the  incubation.  At  the  same  time,  there  was  a  decrease  in 
intensity of the high tool wt bands. 
2 The  degradation  of C3b*  observed  in  Ag:Ab:C is I  mediated.  The  Ag:Ab:C prepared with  C3- 
reconstituted, I-deficient serum (kindly provided by Dr. C. Alper, Harvard University, Cambridge,  MA) 
as a source of complement did not contain the 70-K and 40-K or lower mol wt C3 peptides. M.  E.  MEDOF, K. IIDA, C.  MOLD, AND V.  NUSSENZWEIG  1749 
In  short,  these  experiments  confirm  previous  observations  (7,  8)  that  human 
erythrocytes and I can cleave C3" associated with Ag:Ab:C beyond the iC3b* stage 
and show that the cleavage is CRa dependent. Also, from the comparison in Fig.  7 of 
the effects of H  (32 #g)  +  I  (1.6 #g) with CR1  (0.0025 #g)  +  I, (0.1  #g) we conclude 
that,  on a  molar basis, CRa  is at  least  2  ×  104  times more efficient  than  H  in  the 
degradation of C3 peptides bound to the Ag:Ab:C. As in the case of iC3b* associated 
with cell membranes, a 31-K peptide is generated during this interaction. The precise 
pathway of degradation of the a' chain ofiC3b* is not evident from these experiments. 
Although  the results indicate that  the 31-K band is an end product of the reaction 
and that the 36-K peptide could represent an intermediate, this interpretation requires 
further investigation. 
Discussion 
The mechanisms of C3b  inactivation  have been studied  extensively.  Both  fluid- 
phase C3b and C3b* can be cleaved by I. The former reaction requires  H, and the 
latter can be enhanced by H  (9,  10). In this process, the a' chain is cleaved into major 
fragments of apparent 70 K  and 40 K  tool wt. Both fluid-phase iC3b and iC3b* can 
be  further  cleaved  in  vitro  by plasmin,  elastase,  or  trypsin,  but  the  physiological 
relevance of the breakdown products has remained conjectural  (32,  37, 38). It is also 
known  that  further  degradation  of iC3b*  occurs slowly in  serum.  Fearon  (11)  has 
shown that CR1 can replace H  in the cleavage of fluid-phase C3b to C3bi. Recently, 
some of us have shown  (7)  that release of C3c from soluble IC is mediated by I and 
dependent on binding to human erythrocytes. Moreover, in serum this reaction occurs 
independent  of H. Medicus and Arnaout  (39)  have also reported that breakdown of 
iC3b* can be I-mediated in a  reaction  that was greatly enhanced  by human eryth- 
rocytes. 
Here we show directly that  the human erythrocyte factor mediating this effect is 
CR1. In the presence of I +  purified CR1 or I +  human erythrocytes, C3b* associated 
with EAC 1423b was cleaved into C3c and C3d*. Generation of C3c was inhibited in 
the  presence  of  low  concentrations  of  monoclonal  antibodies  to  CR1.  The  C3c 
fragments released from EAC1423b  and from Ag:Ab:C  (7)  have an ~135-K mol wt 
under nonreducing conditions.  Upon reduction,  major bands of 75 K  (most likely fi 
chain)  and 31K (pI 8.6)  were detected by radioautography. 
One possible interpretation  is that  C3c consists of fl chains,  one 31-K a'-derived 
labeled  peptide,  and a  second weakly radiolabeled  peptide.  The findings  that  two- 
dimensional electrophoresis did not resolve the 31-K band and that two other bands 
at 39 K  and 42 K  not apparent in the radiographs were revealed in the slab gels by 
silver  staining  support  this  possibility.  However,  further  studies  are  necessary  to 
determine  the  precise  structure  of C3c,  the  number  of cleavages  involved  in  its 
production,  and  whether  small  mol  wt  degradation  products  of  C3,  some  with 
biological activity (C3e, C3f, ref. 40-42),  are generated during the fragmentation of 
iC3b* by CR1 +  I. 
The studies  with  soluble Ag:Ab:C  (Figs.  7,  8)  suggest  that  iC3b*  degradation  is 
complex  and  that  it  may  involve  more  than  two  steps  with  the  formation  of 
intermediates. Bands with the mobility of degradation products of fluid-phase C3b; 
that  is,  70  K  and  40  K, were  found  in  variable amounts  in  different  studies  with 
soluble  IC. These fragments could arise from noncovalent  C3b*.  Indeed,  we found 1750  UNIQUE ROLE OF CR~  IN C3b  DEGRADATION 
striking differences in the susceptibility to proteolysis by CRI +  I of fluid-phase C3b 
and  C3b*,  in  that  C3c was  effectively released  only from  the  latter.  For example, 
when 0.25/~g/ml of fluid-phase C3b were incubated for 3 h at 37°C with 200 ng/ml 
of CR1 and 2 btg/ml of I, the end product was mostly iC3b; only small amounts of the 
39  K  and  31  K  fragments were  formed  (Fig.  6).  This  is  to be  contrasted with  the 
treatment of 0.13 ~g/ml of C3b* associated with cell membranes, in which case most 
or all of it was cleaved beyond iC3b*, and C3c released by 100 ng/ml of CR1 +  2/zg/ 
ml of I. The reasons for this difference are not clear but may relate to the nature of 
the bonds between C3b* and the IC, the clustering of C3b during the binding process 
(perhaps allowing the formation of muhivalent bonds with CR1), or the modulating 
activity of neighboring molecules from the IC. 
Although some breakdown  products  can  be  released  from C3b*  by I  +  H,  and 
their structure is similar to those generated by I  +  CR1, CR1 is between  104 and  10  ~ 
times more efficient than H  in promoting fragmentation of C3b*.  Considering that 
the concentration of H  in blood is only about  125 times greater than CR1 (250/~g/ml 
vs.  2/xg/ml),  the  physiological breakdown of C3b*  most  likely takes  place  in  solid 
phase; that is, on the surface of cells  bearing CR1. This is supported by observations 
in vitro and in vivo. When soluble IC are added to human blood in vitro, they bind 
to  various blood elements  in  proportion  to  their  relative  content  of CR1  and  thus 
associate predominantly with CR1 of erythrocytes (5). Incubation with serum factors 
(I +  H)  does not eliminate this interaction  (8).  However, exposure to I of IC bound 
to human erythrocytes causes C3b breakdown and IC release.  Similar processing of 
IC in other species  may occur on other cells  because a  large proportion of Ag:Ab:C 
injected into mice fix complement in vivo and become rapidly associated with platelets 
that, in this species,  bear the majority of C3b receptors (43). 
Of interest  was the finding that CR1 promotes the cleavage of iC3b*. About 75% 
of the C3 label was released as C3c fragments when EAC 1423bi (prepared by treating 
EAC1423b with  H  +  I)  was further incubated with CR1  +  I. The same amount of 
C3c was  released  when  EAC1423bi  was  first  treated  with  CR1,  washed,  and  then 
incubated  with  I. The observations that  EAC1423bi had  no measurable  hemolytic 
activity and  that  almost  no  intact  a'  chains  were  detected  by  SDS-PAGE on  the 
stroma of EAC1423bi argue that  the substrate of the CR1 activity was not residual 
uncleaved C3b*  remaining on the cells.  The simplest  interpretation  of these experi- 
ments is that CR1 can bind iC3b* and that the reaction between C3b*, CR1, and I 
CR1 +  I  CR1 +  I 
proceeds  in  at  least  two  steps: C3b*  iC3b*--  C3c +  C3d*.  A  likely 
implication, therefore, is that CR1 also recognizes particles bearing iC3b*, a property 
that had been previously attributed exclusively to another membrane receptor, termed 
CR3, present on phagocytes as well as other cells  (44). Whether CRa recognizes other 
C3 degradation products (42, 45)  requires further investigation. 
Finally  ,  the  present  results  support  the  idea  that  CR1  is  a  membrane-associated 
regulatory protein  (11,  31)  whose  function  is  to  process  IC  in  vivo  (5-8)  and  are 
probably of relevance to the  understanding of the  pathology of diseases  associated 
with circulating IC. For example, patients with certain connective tissue diseases have 
a deficiency in CR1 on erythrocytes (12, 46)  and kidney glomeruli (47, 48).  Whether 
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process, such a  deficiency could lead to an impairment of inactivation of C3b* and 
contribute to perpetuation of inflammation. 
Summary 
The main finding of this paper is that CR1, the membrane receptor for C3b and 
C4b, together with C3b/C4b-inactivator (I), degrades C3b bound to immune com- 
plexes (C3b*). Two fragments are generated: C3c, which is released from the immune 
complexes,  and  C3d*.  The  C3c  fragment  released  from  the  cell  intermediate 
EAC 1423b prepared with 125I-C3 was analyzed by sodium dodecyl sulfate polyacryl- 
amide gel electrnphoresis (SDS-PAGE) and radioautography. It has a  135,000 mol wt 
and contains disulfide bonded labeled polypeptide chains of 75,000  and 31,000  mol 
wt, which presumably represent the fl and a fragment of the a'-chain of C3b*. Silver 
staining of the SDS-PAGE gels revealed other C3-derived bands with 39-42,000 tool 
wt. Human erythrocytes +  I also cleave C3b* into C3c and C3d*. The activity of the 
erythrocytes  is  CR1  mediated  because  it  can  be  totally  inhibited  by  monoclonal 
antibodies to CR1. 
In contrast with these results, I together with the serum protein/~IH (H) transform 
EAC1423b  into hemolytically inactive EAC1423bi  and cleave the a' chain of C3b* 
into fragments of 70,000 and 40,000 mol wt. Small amounts of C3c are also released 
at relatively high concentrations of H. On a  molar basis, the efficiency of CR1 in the 
generation of C3c and C3d is  104-105 greater than H. 
An additional observation was that C3c could be released by treating EAC1423bi 
with CRa +  I  and that this reaction was also inhibited by monoclonal antibodies to 
CR1.  Therefore,  it  is  likely  that  CR1  has  binding  affinity  for  iC3b  and  that  the 
I  +  CR1  I  +  CRa 
degradation of C3b*  proceeds as follows: C3b*--  iC3b*--  C3c +  C3d*. 
Taken together, our findings argue that the processing of C3b* in vivo occurs in solid 
phase, that is, on the surface of cells bearing CR1. 
Note added in proof" During the preparation of this manuscript, Medicus et al. found 
that  polyclonal  anti-CR1  antibody  also  blocks  enhanced  breakdown  of iC3b*  by 
human  erythrocytes  in  the  presence  of I  in  their  system  (R.  Medicus,  personal 
communication). 
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